目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Recombinant DNA Technology Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Recombinant DNA Technology Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape

Chapter 4. Recombinant DNA Technology Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Recombinant DNA Technology Market: Product Movement Analysis, 2023 & 2030 (USD Billion)
4.3. Medical
4.3.1. Medical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.3.2. Therapeutic Agent
4.3.2.1. Therapeutic Agent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.3.3. Human Protein
4.3.3.1. Human Protein Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.3.4. Vaccine
4.3.4.1. Vaccine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.4. Non-medical
4.4.1. Non-medical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.4.2. Biotech Crops
4.4.2.1. Biotech Crops Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.4.3. Specialty Chemicals
4.4.3.1. Specialty Chemicals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.4.4. Other Non-medical Products
4.4.4.1. Other Non-medical Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Recombinant DNA Technology Market: Component Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Recombinant DNA Technology Market: Component Movement Analysis, 2023 & 2030 (USD Billion)
5.3. Expression System
5.3.1. Expression System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.3.2. Mammalian
5.3.2.1. Mammalian Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.3.3. Bacteria
5.3.3.1. Bacteria Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.3.4. Yeast
5.3.4.1. Yeast Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.3.5. Baculovirus / Insect
5.3.5.1. Baculovirus / Insect Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.3.6. Other Expression Systems
5.3.6.1. Other Expression Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.4. Cloning Vector
5.4.1. Cloning Vector Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Recombinant DNA Technology Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Recombinant DNA Technology Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
6.3. Food & Agriculture
6.3.1. Food & Agriculture Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.4. Health & Disease
6.4.1. Health & Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.4.2. Human
6.4.2.1. Human Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.4.3. Animal
6.4.3.1. Animal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5. Other Applications
6.5.1. Other Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Recombinant DNA Technology Market: End Use Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Recombinant DNA Technology Market: End Use Movement Analysis, 2023 & 2030 (USD Billion)
7.3. Biotechnology and Pharmaceutical Companies
7.3.1. Biotechnology and Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4. Academic & Government Research Institutes
7.4.1. Academic & Government Research Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Other End Uses
7.5.1. Other End Uses Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Recombinant DNA Technology Market: Regional Estimates & Trend Analysis
8.1. Recombinant DNA Technology Market Share, By Region, 2023 & 2030 (USD Billion)
8.2. North America
8.2.1. North America Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.2.2. U.S.
8.2.2.1. U.S. Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.2.3. Canada
8.2.3.1. Canada Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.2.4. Mexico
8.2.4.1. Mexico Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.3. Europe
8.3.1. Europe Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.3.2. UK
8.3.2.1. UK Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.3.3. Germany
8.3.3.1. Germany Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.3.4. France
8.3.4.1. France Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.3.5. Italy
8.3.5.1. Italy Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.3.6. Spain
8.3.6.1. Spain Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.3.7. Denmark
8.3.7.1. Denmark Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.3.8. Sweden
8.3.8.1. Sweden Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.3.9. Norway
8.3.9.1. Norway Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.4. Asia Pacific
8.4.1. Asia Pacific Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.4.2. Japan
8.4.2.1. Japan Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.4.3. China
8.4.3.1. China Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.4.4. India
8.4.4.1. India Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.4.5. South Korea
8.4.5.1. South Korea Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.4.6. Australia
8.4.6.1. Australia Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.4.7. Thailand
8.4.7.1. Thailand Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.5. Latin America
8.5.1. Latin America Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.5.2. Brazil
8.5.2.1. Brazil Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.5.3. Argentina
8.5.3.1. Argentina Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.6. Middle East and Africa
8.6.1. Middle East and Africa Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.6.2. South Africa
8.6.2.1. South Africa Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.6.3. Saudi Arabia
8.6.3.1. Saudi Arabia Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.6.4. UAE
8.6.4.1. UAE Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
8.6.5. Kuwait
8.6.5.1. Kuwait Recombinant DNA Technology Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Heat Map Analysis
9.4. Company Profiles
9.4.1. Pfizer Inc.
9.4.1.1. Participant’s Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Recent Developments/Strategic Initiatives
9.4.2. Sanofi
9.4.2.1. Participant’s Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Recent Developments/Strategic Initiatives
9.4.3. New England Biolabs
9.4.3.1. Participant’s Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Recent Developments/Strategic Initiatives
9.4.4. GlaxoSmithKline plc
9.4.4.1. Participant’s Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Recent Developments/Strategic Initiatives
9.4.5. GenScript
9.4.5.1. Participant’s Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Recent Developments/Strategic Initiatives
9.4.6. Thermo Fisher Scientific Inc.
9.4.6.1. Participant’s Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Recent Developments/Strategic Initiatives
9.4.7. Biogen Inc.
9.4.7.1. Participant’s Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Recent Developments/Strategic Initiatives
9.4.8. Merck & Co., Inc.
9.4.8.1. Participant’s Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Recent Developments/Strategic Initiatives
9.4.9. Amgen Inc.
9.4.9.1. Participant’s Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Recent Developments/Strategic Initiatives
9.4.10. Monsanto Company
9.4.10.1. Participant’s Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Recent Developments/Strategic Initiatives
9.4.11. F. Hoffmann-La Roche Ltd
9.4.11.1. Participant’s Overview
9.4.11.2. Financial Performance
9.4.11.3. Product Benchmarking
9.4.11.4. Recent Developments/Strategic Initiatives
9.4.12. Novartis AG
9.4.12.1. Participant’s Overview
9.4.12.2. Financial Performance
9.4.12.3. Product Benchmarking
9.4.12.4. Recent Developments/Strategic Initiatives
9.4.13. Eli Lilly and Company
9.4.13.1. Participant’s Overview
9.4.13.2. Financial Performance
9.4.13.3. Product Benchmarking
9.4.13.4. Recent Developments/Strategic Initiatives